Skip to main content
Top
Published in: Medical Oncology 7/2014

Open Access 01-07-2014 | Original Paper

GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population

Authors: Chaoyin Jiang, Hua Chen, Lei Shao, Yang Dong

Published in: Medical Oncology | Issue 7/2014

Login to get access

Abstract

Osteosarcoma (OS), the most common primary bone malignancy, occurs primarily in adolescents and young adults. In earlier genome-wide association studies, rs7591996, rs10208273, rs17206779 and rs1906953 were identified as candidate loci for OS in Caucasians but the association of these single-nucleotide polymorphisms (SNPs) with OS in a Chinese Han population remains unknown. We measured the frequency of these four variants in a Chinese Han population to better understand the genetic etiology of OS. Polymerase chain reaction sequencing was used to detect the genotypes of four candidate SNPs in peripheral blood samples collected from 168 OS patients and 216 healthy controls. Logistic regression models were used to estimate the odds ratios and 95 % confidence intervals. We found rs1906953 in the glutamate receptor metabotropic 4 (GRM4) gene was associated significantly with OS in our Chinese Han population; as with the other SNPs, however, no statistically significant difference was detected. Further analysis showed the association between rs1906953 and OS was independent of gender and age. The rs1906953 locus was not associated with Enneking stages or tumor location; however, it was associated significantly with OS metastasis and prognosis. The GRM4 gene polymorphism was associated with the susceptibility and metastasis of OS in a Chinese Han population.
Literature
1.
go back to reference Lietman SA, Joyce MJ. Bone sarcomas: overview of management, with a focus on surgical treatment considerations. Cleve Clin J Med. 2010;77(Suppl 1):S8–12.PubMedCrossRef Lietman SA, Joyce MJ. Bone sarcomas: overview of management, with a focus on surgical treatment considerations. Cleve Clin J Med. 2010;77(Suppl 1):S8–12.PubMedCrossRef
2.
go back to reference Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–43.PubMedCentralPubMedCrossRef Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115(7):1531–43.PubMedCentralPubMedCrossRef
3.
4.
go back to reference Benayahu D, Shur I, Marom R, Meller I, Issakov J. Cellular and molecular properties associated with osteosarcoma cells. J Cell Biochem. 2001;84(1):108–14.PubMedCrossRef Benayahu D, Shur I, Marom R, Meller I, Issakov J. Cellular and molecular properties associated with osteosarcoma cells. J Cell Biochem. 2001;84(1):108–14.PubMedCrossRef
5.
go back to reference Gordon N, Kleinerman ES. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv. 2010;23(4):189–96.PubMedCentralPubMedCrossRef Gordon N, Kleinerman ES. Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine. J Aerosol Med Pulm Drug Deliv. 2010;23(4):189–96.PubMedCentralPubMedCrossRef
6.
go back to reference Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 2009;152:467–78.PubMedCrossRef Gorlick R. Current concepts on the molecular biology of osteosarcoma. Cancer Treat Res. 2009;152:467–78.PubMedCrossRef
7.
go back to reference Subbiah V, Kurzrock R. Phase 1 clinical trials for sarcomas: the cutting edge. Curr Opin Oncol. 2011;23(4):352–60.PubMedCrossRef Subbiah V, Kurzrock R. Phase 1 clinical trials for sarcomas: the cutting edge. Curr Opin Oncol. 2011;23(4):352–60.PubMedCrossRef
9.
go back to reference Foster L, Dall GF, Reid R, Wallace WH, Porter DE. Twentieth-century survival from osteosarcoma in childhood. Trends from 1933 to 2004. J Bone Joint Surg Am Br Vol 2007;89(9):1234–8.CrossRef Foster L, Dall GF, Reid R, Wallace WH, Porter DE. Twentieth-century survival from osteosarcoma in childhood. Trends from 1933 to 2004. J Bone Joint Surg Am Br Vol 2007;89(9):1234–8.CrossRef
10.
go back to reference Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs. 2008;10(5):315–27.PubMedCrossRef Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs. 2008;10(5):315–27.PubMedCrossRef
11.
go back to reference Patio-Garcia A, Sotillo-Pieiro E, Modesto C, Sierrases-Maga L. Analysis of the human tumour necrosis factor-alpha (TNFalpha) gene promoter polymorphisms in children with bone cancer. J Med Genet. 2000;37(10):789–92.PubMedCrossRef Patio-Garcia A, Sotillo-Pieiro E, Modesto C, Sierrases-Maga L. Analysis of the human tumour necrosis factor-alpha (TNFalpha) gene promoter polymorphisms in children with bone cancer. J Med Genet. 2000;37(10):789–92.PubMedCrossRef
12.
go back to reference Ruza E, Sotillo E, Sierrasesumaga L, Azcona C, Patino-Garcia A. Analysis of polymorphisms of the vitamin D receptor, estrogen receptor, and collagen Ialpha1 genes and their relationship with height in children with bone cancer. J Pediatr Hematol Oncol. 2003;25(10):780–6.PubMedCrossRef Ruza E, Sotillo E, Sierrasesumaga L, Azcona C, Patino-Garcia A. Analysis of polymorphisms of the vitamin D receptor, estrogen receptor, and collagen Ialpha1 genes and their relationship with height in children with bone cancer. J Pediatr Hematol Oncol. 2003;25(10):780–6.PubMedCrossRef
13.
go back to reference Savage SA, Burdett L, Troisi R, et al. Germ-line genetic variation of TP53 in osteosarcoma. Pediatr Blood Cancer. 2007;49(1):28–33.PubMedCrossRef Savage SA, Burdett L, Troisi R, et al. Germ-line genetic variation of TP53 in osteosarcoma. Pediatr Blood Cancer. 2007;49(1):28–33.PubMedCrossRef
14.
go back to reference Savage SA, Woodson K, Walk E, et al. Analysis of genes critical for growth regulation identifies Insulin-like Growth Factor 2 Receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2007;16(8):1667–74.CrossRef Savage SA, Woodson K, Walk E, et al. Analysis of genes critical for growth regulation identifies Insulin-like Growth Factor 2 Receptor variations with possible functional significance as risk factors for osteosarcoma. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2007;16(8):1667–74.CrossRef
15.
go back to reference Koshkina NV, Kleinerman ES, Li G, et al. Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J Pediatr Hematol Oncol. 2007;29(12):815–21.PubMedCrossRef Koshkina NV, Kleinerman ES, Li G, et al. Exploratory analysis of Fas gene polymorphisms in pediatric osteosarcoma patients. J Pediatr Hematol Oncol. 2007;29(12):815–21.PubMedCrossRef
16.
go back to reference Toffoli G, Biason P, Russo A, et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(10):3550–6.CrossRef Toffoli G, Biason P, Russo A, et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(10):3550–6.CrossRef
18.
go back to reference Mirabello L, Berndt SI, Seratti GF, et al. Genetic variation at chromosome 8q24 in osteosarcoma cases and controls. Carcinogenesis. 2010;31(8):1400–4.PubMedCentralPubMedCrossRef Mirabello L, Berndt SI, Seratti GF, et al. Genetic variation at chromosome 8q24 in osteosarcoma cases and controls. Carcinogenesis. 2010;31(8):1400–4.PubMedCentralPubMedCrossRef
19.
go back to reference Mirabello L, Yu K, Berndt SI, et al. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer. 2011;11:209.PubMedCentralPubMedCrossRef Mirabello L, Yu K, Berndt SI, et al. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer. 2011;11:209.PubMedCentralPubMedCrossRef
20.
go back to reference He ML, Wu Y, Zhao JM, Wang Z, Chen YB. PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population. Asian Pac J Cancer Prev APJCP. 2013;14(9):5117–22.CrossRef He ML, Wu Y, Zhao JM, Wang Z, Chen YB. PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma in a Chinese population. Asian Pac J Cancer Prev APJCP. 2013;14(9):5117–22.CrossRef
21.
go back to reference Both J, Wu T, Bras J, et al. Identification of novel candidate oncogenes in chromosome region 17p11.2-p12 in human osteosarcoma. PLoS One. 2012;7(1):e30907.PubMedCentralPubMedCrossRef Both J, Wu T, Bras J, et al. Identification of novel candidate oncogenes in chromosome region 17p11.2-p12 in human osteosarcoma. PLoS One. 2012;7(1):e30907.PubMedCentralPubMedCrossRef
22.
go back to reference Yang W, He M, Zhao J, Wang Z. Association of ITGA3 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma. Med Oncol. 2014;31(2):826.PubMedCrossRef Yang W, He M, Zhao J, Wang Z. Association of ITGA3 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma. Med Oncol. 2014;31(2):826.PubMedCrossRef
24.
go back to reference International HapMap C, Frazer KA, Ballinger DG, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449(7164):851–61.PubMedCrossRef International HapMap C, Frazer KA, Ballinger DG, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007;449(7164):851–61.PubMedCrossRef
25.
go back to reference Savage SA, Mirabello L, Wang Z, et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 2013;45(7):799–803.PubMedCentralPubMedCrossRef Savage SA, Mirabello L, Wang Z, et al. Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet. 2013;45(7):799–803.PubMedCentralPubMedCrossRef
26.
go back to reference Banerjee PK, Snead OC 3rd. Presynaptic gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB (GABAB) receptor-mediated release of GABA and glutamate (GLU) in rat thalamic ventrobasal nucleus (VB): a possible mechanism for the generation of absence-like seizures induced by GHB. J Pharmacol Exp Ther. 1995;273(3):1534–43.PubMed Banerjee PK, Snead OC 3rd. Presynaptic gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB (GABAB) receptor-mediated release of GABA and glutamate (GLU) in rat thalamic ventrobasal nucleus (VB): a possible mechanism for the generation of absence-like seizures induced by GHB. J Pharmacol Exp Ther. 1995;273(3):1534–43.PubMed
27.
go back to reference Hu RQ, Banerjee PK, Snead OC 3rd. Regulation of gamma-aminobutyric acid (GABA) release in cerebral cortex in the gamma-hydroxybutyric acid (GHB) model of absence seizures in rat. Neuropharmacology. 2000;39(3):427–39.PubMedCrossRef Hu RQ, Banerjee PK, Snead OC 3rd. Regulation of gamma-aminobutyric acid (GABA) release in cerebral cortex in the gamma-hydroxybutyric acid (GHB) model of absence seizures in rat. Neuropharmacology. 2000;39(3):427–39.PubMedCrossRef
28.
go back to reference Skerry TM, Genever PG. Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci. 2001;22(4):174–81.PubMedCrossRef Skerry TM, Genever PG. Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci. 2001;22(4):174–81.PubMedCrossRef
29.
go back to reference Nedergaard M, Takano T, Hansen AJ. Beyond the role of glutamate as a neurotransmitter. Nat Rev Neurosci. 2002;3(9):748–55.PubMedCrossRef Nedergaard M, Takano T, Hansen AJ. Beyond the role of glutamate as a neurotransmitter. Nat Rev Neurosci. 2002;3(9):748–55.PubMedCrossRef
30.
go back to reference Hinoi E, Takarada T, Ueshima T, Tsuchihashi Y, Yoneda Y. Glutamate signaling in peripheral tissues. Euro J Biochem FEBS. 2004;271(1):1–13.CrossRef Hinoi E, Takarada T, Ueshima T, Tsuchihashi Y, Yoneda Y. Glutamate signaling in peripheral tissues. Euro J Biochem FEBS. 2004;271(1):1–13.CrossRef
31.
go back to reference Hinoi E, Takarada T, Yoneda Y. Glutamate signaling system in bone. J Pharmacol Sci. 2004;94(3):215–20.PubMedCrossRef Hinoi E, Takarada T, Yoneda Y. Glutamate signaling system in bone. J Pharmacol Sci. 2004;94(3):215–20.PubMedCrossRef
32.
go back to reference Martin TJ, Seeman E. Bone remodelling: its local regulation and the emergence of bone fragility. Best Pract Res Clin Endocrinol Metab. 2008;22(5):701–22.PubMedCrossRef Martin TJ, Seeman E. Bone remodelling: its local regulation and the emergence of bone fragility. Best Pract Res Clin Endocrinol Metab. 2008;22(5):701–22.PubMedCrossRef
33.
go back to reference Sharma MK, Seidlitz EP, Singh G. Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem Biophys Res Commun. 2010;391(1):91–5.PubMedCrossRef Sharma MK, Seidlitz EP, Singh G. Cancer cells release glutamate via the cystine/glutamate antiporter. Biochem Biophys Res Commun. 2010;391(1):91–5.PubMedCrossRef
34.
go back to reference Doxsee DW, Gout PW, Kurita T, et al. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate. 2007;67(2):162–71.PubMedCrossRef Doxsee DW, Gout PW, Kurita T, et al. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate. 2007;67(2):162–71.PubMedCrossRef
35.
go back to reference Kalariti N, Lembessis P, Koutsilieris M. Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Res. 2004;24(6):3923–9.PubMed Kalariti N, Lembessis P, Koutsilieris M. Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Res. 2004;24(6):3923–9.PubMed
36.
go back to reference Molyneux SD, Di Grappa MA, Beristain AG, et al. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Investig. 2010;120(9):3310–25.PubMedCentralPubMedCrossRef Molyneux SD, Di Grappa MA, Beristain AG, et al. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. J Clin Investig. 2010;120(9):3310–25.PubMedCentralPubMedCrossRef
37.
go back to reference Griffin KJ, Kirschner LS, Matyakhina L, et al. A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions. J Med Genet. 2004;41(12):923–31.PubMedCentralPubMedCrossRef Griffin KJ, Kirschner LS, Matyakhina L, et al. A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions. J Med Genet. 2004;41(12):923–31.PubMedCentralPubMedCrossRef
38.
go back to reference Dixon AL, Liang L, Moffatt MF, et al. A genome-wide association study of global gene expression. Nat Genet. 2007;39(10):1202–7.PubMedCrossRef Dixon AL, Liang L, Moffatt MF, et al. A genome-wide association study of global gene expression. Nat Genet. 2007;39(10):1202–7.PubMedCrossRef
39.
go back to reference Zeller T, Wild P, Szymczak S, et al. Genetics and beyond—the transcriptome of human monocytes and disease susceptibility. PLoS One. 2010;5(5):e10693.PubMedCentralPubMedCrossRef Zeller T, Wild P, Szymczak S, et al. Genetics and beyond—the transcriptome of human monocytes and disease susceptibility. PLoS One. 2010;5(5):e10693.PubMedCentralPubMedCrossRef
40.
go back to reference Fairfax BP, Makino S, Radhakrishnan J, et al. Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat Genet. 2012;44(5):502–10.PubMedCentralPubMedCrossRef Fairfax BP, Makino S, Radhakrishnan J, et al. Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat Genet. 2012;44(5):502–10.PubMedCentralPubMedCrossRef
41.
go back to reference Consortium EP, Birney E, Stamatoyannopoulos JA, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447(7146):799–816.PubMedCrossRef Consortium EP, Birney E, Stamatoyannopoulos JA, et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature. 2007;447(7146):799–816.PubMedCrossRef
43.
go back to reference Cotterill SJ, Wright CM, Pearce MS, Craft AW, Group UMBTW. Stature of young people with malignant bone tumors. Pediatr Blood Cancer. 2004;42(1):59–63.PubMedCrossRef Cotterill SJ, Wright CM, Pearce MS, Craft AW, Group UMBTW. Stature of young people with malignant bone tumors. Pediatr Blood Cancer. 2004;42(1):59–63.PubMedCrossRef
44.
go back to reference Longhi A, Pasini A, Cicognani A, et al. Height as a risk factor for osteosarcoma. J Pediatr Hematol Oncol. 2005;27(6):314–8.PubMedCrossRef Longhi A, Pasini A, Cicognani A, et al. Height as a risk factor for osteosarcoma. J Pediatr Hematol Oncol. 2005;27(6):314–8.PubMedCrossRef
45.
go back to reference Mirabello L, Pfeiffer R, Murphy G, et al. Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control CCC. 2011;22(6):899–908.PubMedCentralPubMedCrossRef Mirabello L, Pfeiffer R, Murphy G, et al. Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control CCC. 2011;22(6):899–908.PubMedCentralPubMedCrossRef
46.
go back to reference Chang HJ, Yoo BC, Lim SB, et al. Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11(9):3288–95.CrossRef Chang HJ, Yoo BC, Lim SB, et al. Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res Off J Am Assoc Cancer Res. 2005;11(9):3288–95.CrossRef
47.
go back to reference Brocke KS, Staufner C, Luksch H, et al. Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther. 2010;9(6):455–68.PubMedCrossRef Brocke KS, Staufner C, Luksch H, et al. Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther. 2010;9(6):455–68.PubMedCrossRef
48.
go back to reference Stepulak A, Luksch H, Gebhardt C, et al. Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol. 2009;132(4):435–45.PubMedCrossRef Stepulak A, Luksch H, Gebhardt C, et al. Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol. 2009;132(4):435–45.PubMedCrossRef
49.
go back to reference Luksch H, Uckermann O, Stepulak A, et al. Silencing of selected glutamate receptor subunits modulates cancer growth. Anticancer Res. 2011;31(10):3181–92.PubMed Luksch H, Uckermann O, Stepulak A, et al. Silencing of selected glutamate receptor subunits modulates cancer growth. Anticancer Res. 2011;31(10):3181–92.PubMed
Metadata
Title
GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population
Authors
Chaoyin Jiang
Hua Chen
Lei Shao
Yang Dong
Publication date
01-07-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 7/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0050-4

Other articles of this Issue 7/2014

Medical Oncology 7/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.